fbpx
EVENTS|NEWS|CONTACT|DONATE
Read Our Newsletter

News in Gastric Cancer

News from around the world, curated by the Gastric Cancer Foundation.
lonsurf
Nov 13 2018

FDA Grants Priority Review to TAS-102 for Gastric/GEJ Cancer

Shared in OncLive, the FDA has granted priority review to a supplemental new drug application for TAS-102 (trifluridine/tipiracil; Lonsurf) for use in previously treated patients with advanced or metastatic gastric adenocarcinoma, including cancer of the gastroesophageal junction.

Read Source
, ,

Social Media

   

Newsroom

For press inquiries about the Gastric Cancer Foundation, please contact: Mediainfo@gastriccancer.org

Please join with us to fuel the next wave of progress.

Your support today will honor the memories of those we have lost and create much-needed hope for those who are bravely facing the disease today. Contributions are tax-deductible.
Please join with us to fuel the next wave of progress. Support our 2024 Fundraising Campaign.

Your support today will honor the memories of those we have lost and create much-needed hope for those who are bravely facing the disease today. Contributions are tax-deductible.

Together, we will defeat stomach cancer.

Together, we will defeat stomach cancer.

MORE INFODONATE
X